Gastroenterology
Volume 128, Issue 7 , Pages 2164-2166 , June 2005

Treatment of Crohn’s Disease: The “Long” of It

  • Stephen B. Hanauer

      Affiliations

    • Section of Gastroenterology, Nutrition, and Hepatology, Department of Medicine, The University of Chicago, Chicago, Illinois
    • Corresponding Author InformationAddress reprint requests to: Stephen B. Hanauer, MD, Professor of Medicine and Clinical Pharmacology, Chief, Section of Gastroenterology, Nutrition, and Hepatology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637; fax: (717) 702-2182.
    • ,
  • Ronald A. Thisted

      Affiliations

    • Department of Health Studies, The University of Chicago, Chicago, Illinois

References 

  1. Lemann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, et al. A randomized double-blind controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine . Gastroenterology . 2005;128:1812–1818
  2. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine [see comments] . Lancet . 1996;347:215–219
  3. Pearson DC , May GR , Fick G , Sutherland LR . Azathioprine for maintaining remission of Crohn’s disease . Cochrane Database Syst Rev . 2000;CD000067
  4. Aberra FN , Lichtenstein GR . Review article (monitoring of immunomodulators in inflammatory bowel disease) . Aliment Pharmacol Ther . 2005;21:307–319
  5. Lichtenstein GR . Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy . Gastroenterology . 2004;127:1558–1564
  6. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo (a 2-year trial) . Gastroenterology . 2004;127:723–729
  7. Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease . Gastroenterology . 2004;127:730–740
  8. Sandborn WJ , Feagan BG . The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn’s disease remains uncertain . Gastroenterology . 2004;127:990–993
  9. Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, et al. Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission under treatment is associated with a high risk of relapse (abstract) . Gastroenterology . 2004;126(Suppl 2):A-113
  10. Vermeire S , Van Assche G , Rutgeerts P . C-reactive protein as a marker for inflammatory bowel disease . Inflamm Bowel Dis . 2004;10:661–665
  11. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives . Gastroenterology . 1990;98:811–818
  12. Cosnes J , Beaugerie L , Carbonnel F , Gendre JP . Smoking cessation and the course of Crohn’s disease (an intervention study) . Gastroenterology . 2001;120:1093–1099

PII: S0016-5085(05)00702-X

doi: 10.1053/j.gastro.2005.04.018

Gastroenterology
Volume 128, Issue 7 , Pages 2164-2166 , June 2005

Article Tools